Financial Snapshot
Revenues
Revenues
Revenue YoY Change
Revenues
Expenses
Cost Of Revenues
Gross Profit
Gross Profit Margin
Gross Profit
Selling, General & Admin Expense
Research & Development
Depreciation, Depletion & Amortization
SGA Expense to Gross Profit Ratio
R&D To Gross Profit Ratio
DDA To Gross Profit Ratio
Operating Expenses Total
Operating Profits/Loss
Operational Expenses
Interest Expenses
Interest Expenses To Operating Income %
Other Expense/Income
Interest & Other Expense/Income
Income/Loss
Pretax Income
Income Tax
Net Profits/Loss
Pretax Income YoY Change
Income Tax Rate
Net Profits/Loss YoY Change
Basic EPS
Net Income To Revenue Ratio
Pretax & Net Income
Assets & Liabilities
Cash & Short-Term Investments
Cash & Equivalents
Cash To Operating Expenses Ratio
Inventory
Receivables
Total Short-Term Assets
Property, Plant And Equipment
Long-Term Investments
Total Long-Term Assets
Total Assets
Net Income To Total Assets Percentage
Accounts Payable
Short-Term Debt
Long Term Debt Due
Total Short-Term Liabilities
Long-Term Debt
Other Long-Term Liabilities
Total Long-Term Liabilities
Total Liabilities
Short-Term To Long-Term Debt Ratio
Short-Term Assets To Debt Ratio
Long-Term Debt To Net Income Ratio
Assets & Liabilities
Ownership
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares
Stock Issuance & Repurchase
Ownership Data
Return On Shareholders' Equity
Book Value
Free Cash Flow
Free Cash Flow YoY
Free Cash Flow Margin
Dividends
Dividends
Stock Price
About IR-Med, Inc.
IR-Med, Inc. is engaged in the designing and developing devices utilizing spectrographic usability medical devices based on the combination of Infra-Red (IR) and Artificial Intelligence (AI) technologies. The company is headquartered in New York City, New York and currently employs 6 full-time employees. The company went IPO on 2001-07-18. The firm is engaged in developing its technology through its subsidiary and is utilizing Infra-Red-light spectroscopy (IR) combined with artificial intelligence (AI) technology platform to develop non-invasive devices for various medical indications, by detecting and measuring various biomarkers and molecules in the blood and in human tissue in real-time. The firm has three principal medical devices in development. Its product under development, PressureSafe, is a handheld optical monitoring device that is being developed to support early detection of pressure injuries (PI) to the skin and underlying tissue. DiaSafe is a handheld optical monitoring device that is being developed to support early detection of DFUs in lower limb skin and underlying tissue. Nobiotics is an otoscope designed to support physicians with an immediate indication as to whether a mid-ear infection (otitis media) is of a bacterial origin.
Industry: Electromedical & Electrotherapeutic Apparatus Peers: ABBOTT LABORATORIES KNOW LABS, INC. Co-Diagnostics, Inc. DAXOR CORP electroCore, Inc. IRIDEX CORP Owlet, Inc. PRECISION OPTICS CORPORATION, INC. VASO Corp
